See more : Copperwired Public Company Limited (CPW.BK) Income Statement Analysis – Financial Results
Complete financial analysis of BioVie Inc. (BIVI) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of BioVie Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Shandong Lukang Pharmaceutical Co.,Ltd. (600789.SS) Income Statement Analysis – Financial Results
- Wool Industry Tria Alfa S.A. (AAAK.AT) Income Statement Analysis – Financial Results
- M/I Homes, Inc. (MHO) Income Statement Analysis – Financial Results
- Zhejiang Truelove Vogue Co., Ltd. (003041.SZ) Income Statement Analysis – Financial Results
- Risanamento SpA (RN.MI) Income Statement Analysis – Financial Results
BioVie Inc. (BIVI)
About BioVie Inc.
BioVie Inc., a clinical stage biotechnology company, engages in the discovery, development, and commercialization of drugs therapies in the United States. Its products in pipeline include BIV201, which completed Phase IIa clinical trial for the treatment of ascites due to chronic liver cirrhosis; and NE3107, which is in Phase III clinical trial for the treatment of patients with mild to moderate Alzheimer's disease and Phase I clinical trial for the treatment of Parkinson's disease. The company is also developing NE3107, which is in pre-clinical stage for the treatment of multiple myeloma and prostate cancer. The company was formerly known as NanoAntibiotics, Inc. and changed its name to BioVie Inc. in July 2016. BioVie Inc. was incorporated in 2013 and is based in Carson City, Nevada.
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 229.38K | 266.84K | 237.42K | 229.38K | 229.38K | 229.38K | 229.38K | 229.38K | 51.04K | 0.00 | 0.00 | 0.00 |
| Gross Profit | -229.38K | -266.84K | -237.42K | -229.38K | -229.38K | -229.38K | -229.38K | -229.38K | -51.04K | 0.00 | 0.00 | 0.00 |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 23.10M | 33.30M | 17.26M | 133.19M | 1.15M | 1.01M | 370.85K | 466.35K | 37.90K | 4.20K | 49.42K | 0.00 |
| General & Administrative | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 1.26M | 1.77M | 857.88K | 343.09K | 229.18K | 272.97K | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 8.85M | 11.55M | 9.77M | 4.64M | 1.31M | 1.26M | 1.77M | 857.88K | 343.09K | 229.18K | 272.97K | 70.06K |
| Other Expenses | 0.00 | 229.38M | 229.38K | 229.38K | 229.38K | 229.38K | 229.38K | 229.38K | 51.04K | 212.71K | 247.08K | 0.00 |
| Operating Expenses | 31.95M | 45.08M | 27.25M | 138.05M | 2.69M | 2.50M | 2.37M | 1.55M | 432.03K | 233.38K | 322.39K | 70.06K |
| Cost & Expenses | 32.18M | 45.08M | 27.25M | 138.05M | 2.69M | 2.50M | 2.37M | 1.55M | 432.03K | 233.38K | 322.39K | 70.06K |
| Interest Income | 1.14M | 562.26K | 44.08K | 21.97K | 234.00 | 1.16K | 4.00 | 14.00 | 186.00 | 369.00 | 489.00 | 20.00 |
| Interest Expense | 2.89M | 4.30M | 2.16M | 559.46K | 4.77M | 273.00 | 40.96K | 0.00 | 81.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 229.38K | 266.84K | 237.42K | 229.38K | 229.38K | 229.38K | 229.38K | 229.38K | 51.04K | 369.00 | 489.00 | 70.06K |
| EBITDA | -31.95M | -45.69M | -23.68M | -137.80M | -2.46M | -2.27M | -2.14M | -1.32M | -380.81K | -233.01K | -321.90K | 20.00 |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -32.18M | -45.08M | -27.25M | -138.05M | -2.69M | -2.50M | -2.37M | -1.55M | -432.03K | -233.38K | -322.39K | -70.06K |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | 59.05K | -5.18M | 1.17M | 7.80M | -13.98M | 52.29K | -40.96K | 222.94K | 105.00 | 369.00 | 489.00 | 20.00 |
| Income Before Tax | -32.12M | -50.26M | -26.08M | -130.25M | -16.68M | -2.44M | -2.41M | -1.33M | -431.92K | -233.01K | -321.90K | -70.04K |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 0.00 | 4.30M | -3.29M | 559.46K | 4.77M | -51.40K | -1.00 | -222.93K | -105.00 | -369.00 | -489.00 | 20.00 |
| Net Income | -32.12M | -50.26M | -26.08M | -183.85M | -33.78M | -2.49M | -2.43M | -1.33M | -431.92K | -233.01K | -321.90K | -70.04K |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -7.30 | -15.47 | -10.58 | -148.23 | -68.52 | -9.82 | -31.77 | -18.61 | -6.19 | -3.34 | -4.62 | 0.00 |
| EPS Diluted | -7.30 | -15.50 | -10.60 | -148.23 | -68.52 | -9.82 | -31.77 | -18.61 | -6.19 | -3.34 | -4.62 | 0.00 |
| Weighted Avg Shares Out | 4.52M | 3.24M | 2.46M | 1.24M | 492.00K | 253.00K | 76.00K | 71.00K | 69.00K | 69.00K | 69.00K | 32.98K |
| Weighted Avg Shares Out (Dil) | 4.52M | 3.25M | 2.47M | 1.24M | 492.95K | 253.96K | 76.61K | 71.51K | 69.76K | 69.77K | 69.67K | 32.98K |
BioVie Inc. Class Action: Levi & Korsinsky Reminds BioVie Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of March 19, 2024 - BIVI
NEW YORK, NY / ACCESSWIRE / March 10, 2024 / If you suffered a loss on your BioVie Inc. (NASDAQ:BIVI) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more...
Levi & Korsinsky Reminds BioVie Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of March 19, 2024 - BIVI
NEW YORK, NY / ACCESSWIRE / March 9, 2024 / If you suffered a loss on your BioVie Inc. (NASDAQ:BIVI) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more...
MARCH 19 DEADLINE: The Schall Law Firm Encourages Investors in BioVie Inc. with Losses of $100,000 to Contact the Firm
LOS ANGELES, CA / ACCESSWIRE / March 9, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against BioVie Inc. ("BioVie" or "the Company") (NASDAQ:BIVI) for violations of 10(b) and...
Levi & Korsinsky Notifies BioVie Inc. Investors of a Class Action Lawsuit and Upcoming Deadline – BIVI
NEW YORK, NY / ACCESSWIRE / March 8, 2024 / If you suffered a loss on your BioVie Inc. (NASDAQ:BIVI) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more...
BIVI Investors Have Opportunity to Lead BioVie Inc. Securities Fraud Lawsuit
BENSALEM, Pa. , March 8, 2024 /PRNewswire/ -- Law Offices of Howard G.
Levi & Korsinsky Reminds BioVie Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of March 19, 2024 - BIVI
NEW YORK, NY / ACCESSWIRE / March 8, 2024 / If you suffered a loss on your BioVie Inc. (NASDAQ:BIVI) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more...
Levi & Korsinsky Notifies BioVie Inc. Investors of a Class Action Lawsuit and Upcoming Deadline - BIVI
NEW YORK, NY / ACCESSWIRE / March 8, 2024 / If you suffered a loss on your BioVie Inc. (NASDAQ:BIVI) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more...
Levi & Korsinsky Notifies BioVie Inc. Investors of a Class Action Lawsuit and Upcoming Deadline - BIVI
NEW YORK, NY / ACCESSWIRE / March 8, 2024 / If you suffered a loss on your BioVie Inc. (NASDAQ:BIVI) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more...
Levi & Korsinsky Reminds BioVie Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of March 19, 2024 - BIVI
NEW YORK, NY / ACCESSWIRE / March 8, 2024 / If you suffered a loss on your BioVie Inc. (NASDAQ:BIVI) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more...
FINAL DEADLINE APPROACHING: The Schall Law Firm Encourages Investors in BioVie Inc. with Losses of $100,000 to Contact the Firm
LOS ANGELES, CA / ACCESSWIRE / March 8, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against BioVie Inc. ("BioVie" or "the Company") (NASDAQ:BIVI) for violations of §§10(b) and...
Source: https://incomestatements.info
Category: Stock Reports